Document:

Exhibit 10.35 

LABORATORY CORPORATION
OF AMERICA HOLDINGS 

AMENDMENT 

TO 

MASTER SENIOR
EXECUTIVE SEVERANCE PLAN 

        The
Laboratory Corporation of America Holdings Master Senior Executive Severance Plan (the
“Plan”) is hereby amended as set forth below, effective as of the date of
adoption of this Amendment by the Board of Directors of Laboratory Corporation of America
Holdings (the “Corporation”), as provided below: 

         1.       
          Section 1.9 of the Plan is amended to read in its entirety as follows: 

	  	        Good
Reason” shall mean: 

	  	        (a) a material reduction in the base salary or targeted bonus as a percent of a base
                    salary without the consent of the employee; 

	  	        (b) relocation to an office location more than 75 miles from the employee’s
                    current office without the consent of the employee; or  

	  	        (c) a substantial reduction in job responsibilities and duties or transfer to
                    another job without the consent of the employee 

	  	        Notwithstanding
the foregoing, “Good Reason” shall not include a reduction in base salary or
target bonus of the Covered Employee where such reduction is pursuant to a Company-wide
reduction of base salaries and/or target bonuses. 

         2.       
          Section 1.11 of the Plan is amended to read in its entirety as follows: 

	  	        Qualifying
Termination” shall mean: 

	  	        (a) involuntary termination without Cause;  

	  	        (b) voluntary termination with Good Reason; however, not withstanding the foregoing,
                    the voluntary termination by the Covered Employee must occur within 90 days
                    after the occurrence of the Good Reason and after the Company has received
                    notice of the Good Reason event and failed to cure within 30 days after
                    receiving such notice. Otherwise, such termination shall be considered voluntary
                    termination without Good Reason and not a Qualifying Termination; or 

	  	        (c) Involuntary termination without Cause or Voluntary Termination with Good Reason
                    within 36 months following a Change in Control. 

	  	        Notwithstanding
the foregoing, “Qualifying Termination” shall not mean any termination of an
employee’s employment with the Company by reason of death, disability, or retirement
of the employee. 

         3.       
          Section 1.16 shall be added to the Plan as follows:

	  	        “Termination”
shall cover all terminations of employment referred to under this Plan and shall mean a
“separation from service” as defined in Section 409A of the Internal Revenue
Code of 1986, as amended. 

         4.       
          Section 3.1 of the Plan is amended to read in its entirety as follows: 

	  	        “Amount
of Severance. Subject to Sections 3.2 and 3.3, upon the occurrence of a Qualifying
Termination and the execution by the employee of a Special Severance Agreement in
substantially the form attached as Exhibit A (such agreement to be executed within 30 days
of the Qualifying Termination or within 45 days of the Qualifying Termination if necessary
to comply with the requirements of the Age Discrimination in Employment Act of 1967),
which will contain, among other things, noncompetition, nonsolicitation, duty of loyalty,
confidentiality, and release provisions that shall apply to each severance arrangement
during, and in certain instances after, the time when any severance payments are being
made to each employee, the Company shall pay Severance Pay to a Covered Employee in an
amount equal to the mathematical product of multiplying the factor shown on Schedule 1 for
the Designated Group to which the employee belongs at the time of termination, times such
employee’s Base Salary, plus Target Bonus. Additionally, such Covered Employee shall
be entitled, for up to six months following a Qualifying Termination, to payment by the
Company of the Applicable Premium for the continuation of those health benefits for which
he or she qualified at the time of the Qualifying Termination, pursuant to the
Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA). 

         5.       
          Section 5.1 of the Plan is amended to read in its entirety as follows: 

	  	        “Severance
Pay. The Company shall pay the Covered Employee the amount to which he or she is entitled
under Section 3.1 as follows: (a) 50 percent of the total Severance Pay due, less
statutory deductions, shall be paid within 30 days following the execution of a Special
Severance Agreement; and (b) the remaining 50 percent of Severance Pay, less statutory
deductions, shall be paid within 30 days following the one-year anniversary of the
execution of the Special Severance Agreement, but only if the employee has complied in all
material respects with the terms and conditions of the Special Severance Agreement.
Notwithstanding the foregoing, all payments due hereunder shall be completed within 24
months of the termination of the Covered Employee’s employment, but payments shall be
due hereunder only if the employee has complied in all material respects with the terms
and conditions of the Special Severance Agreement. Each payment specified under this
Section 5.1 shall be deemed to be separate payments. 

	  	        “Anything
in this Agreement to the contrary notwithstanding, if (A) on the date of termination of a
Covered Employee’s employment with the Company or a subsidiary, any of the
Company’s stock is publicly traded on an established securities market or otherwise
(within the meaning of Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as
amended (the “Code”)), (B) if the Covered Employee is determined to be a
“specified employee” within the meaning of Section 409A(a)(2)(B) of the Code,
(C) the payments exceed the amounts permitted to be paid pursuant to Treasury Regulations
section 1.409A-1(b)(9)(iii) and (D) such delay is required to avoid the imposition of the
tax set forth in Section 409A(a)(1) of the Code, as a result of such termination, the
Covered Employee would receive any payment that, absent the application of this Section
8.4, would be subject to interest and additional tax imposed pursuant to Section 409A(a)
of the Code as a result of the application of Section 409A(2)(B)(i) of the Code, then no
such payment shall be payable prior to the date that is the earliest of (1) 6 months after
the Covered Employee’s termination date, (2) the Covered Employee’s death or (3)
such other date as will cause such payment not to be subject to such interest and
additional tax (with a catch-up payment equal to the sum of all amounts that have been
delayed to be made as of the date of the initial payment). 

	  	        “It
is the intention of the parties that payments or benefits payable under this Agreement not
be subject to the additional tax imposed pursuant to Section 409A of the Code. To the
extent such potential payments or benefits could become subject to such Section, the
Company amend this Agreement with the goal of giving the Covered Employee the economic
benefits described herein in a manner that does not result in such tax being imposed. 

        Except as amended above, the Plan
shall remain unchanged in all other respects. 

         
          This Amendment to the Plan was duly adopted and approved by the Board of Directors of the Corporation on
December 6th, 2007.exv10w44

 

Exhibit 10.44

January 6, 2008

AGREEMENT

     This Settlement and Release Agreement is made and entered into as of the date of the last
PARTY to sign the Agreement below (the “Effective Date”), by and between Affymetrix, Inc., a
corporation organized under the laws of the State of Delaware having a principal place of business
at 3380 Central Expressway, Santa Clara, CA 9505, (“AFFYMETRIX”) on behalf of itself and its
AFFILIATES, their successors and assigns, and Illumina, Inc., a corporation organized under the
laws of the State of Delaware having a principal place of business at 9885 Towne Center Drive, San
Diego, California, 92121 (“ILLUMINA”) on behalf of itself and its AFFILIATES, their successors and
assigns. The signatories to this Agreement are sometimes referred to herein jointly as the
“PARTIES” and individually as a “PARTY”.

     WHEREAS, AFFYMETRIX has filed the ACTIONS in the United States District Court for the District
of Delaware, in Regional Court in Düsseldorf (Germany), and in the High Court of Justice, Chancery
Division — Patents Court in London (United Kingdom);

     WHEREAS, to avoid the necessity, expense, inconvenience and uncertainty of additional or
continued litigation, the Parties wish to settle the disputes between them in the ACTIONS and to
resolve and preclude certain related and other claims as provided herein; and

     WHEREAS, AFFYMETRIX and ILLUMINA wish to avoid the uncertainties and costs associated with
pursuing the ACTIONS and any controversy or litigation relating to thereto, and they mutually
desire to resolve their differences concerning the Actions and all claims and causes of action set
forth in or contemplated thereby on the following terms and conditions.

     NOW, THEREFORE, for good and valuable consideration, including, without limitation, the
releases and mutual promises contained herein, the receipt of which is hereby acknowledged, the
Parties agree as follows:

I. DEFINITIONS

1.1 “ACTIONS” means individually and collectively,

   (i) Affymetrix, Inc. v. Illumina, Inc., United States District Court for the District of
Delaware, Civil Action No. 04-901-JJF filed July 26, 2004;

   (ii) Affymetrix, Inc. v. Illumina, Inc., United States District Court for the District of
Delaware Civil Action No. 07-670-JJF filed October 24, 2007;

Confidential

Covered by FRE 408 and any state counterpart

1

 

January 6, 2008

   (iii) Affymetrix, Inc. v. Illumina GmbH and Illumina, Inc., in Regional Court in Düsseldorf
(Germany) filed October 24, 2007; and

   (iv) Affymetrix, Inc. v. Illumina UK Ltd. and Illumina, Inc., in the High Court of Justice,
Chancery Division — Patents Court in London (United Kingdom) filed October 24, 2007.

1.2 “AFFILIATE” means any entity that is, directly or indirectly, controlling, controlled by or
under common control with either PARTY, but only so long as such Control exists. As used in this
Section 1.2, “Control” of an entity means the possession, directly or indirectly, of the power to
direct or cause the direction of the management and policies of such entity, whether through the
ownership of voting securities (or other ownership interest), by contract or otherwise..

1.3 “BLOCKING PATENTS” means all patents and applications therefor, anywhere in the world,
currently as of the Effective Date or at any time thereafter, owned by AFFYMETRIX (or by an
AFFYMETRIX AFFILIATE) or under which AFFYMETRIX (or an AFFYMETRIX AFFILIATE) has the right to grant
licenses or sublicenses, having a claim that covers a CURRENT PRODUCT.

1.4 “CHANGE OF CONTROL” means any transaction or series of related transactions with respect to any
PARTY, including any such transaction(s) in bankruptcy, in which, a person or group of related
persons who do not Control such PARTY prior to such transaction or series of transactions,
subsequently obtain(s) Control of such PARTY by any means, whether by operation of law, acquisition
of securities, merger, contract, acquisition of assets, or otherwise. As used in this Section 1.4,
“Control” of an entity means the possession, directly or indirectly, of the power to direct or
cause the direction of the management and policies of such entity, whether through the ownership of
voting securities (or other ownership interest), by contract or otherwise.

1.5 “CURRENT PRODUCTS” means (i) any products of ILLUMINA’s (or an ILLUMINA AFFILIATE’s) product
line commercialized by ILLUMINA or by an ILLUMINA AFFILIATE as of the Effective Date, (ii) any
products resulting from ILLUMINA’s (or from an ILLUMINA AFFILIATE’s) research and development
efforts, as of the Effective Date, publicly announced or documented in ILLUMINA’s (or in an
ILLUMINA AFFILIATE’s) formal product development process, and (iii) all EVOLUTIONARY IMPROVEMENTS
to products of categories (i) and (ii).

1.6 “EVOLUTIONARY IMPROVEMENTS” means modifications, revisions, additions, enhancements, changes or
similar alterations to an original product, to enhance the original product in terms of its
performance and/or functionality, and in which the original product retains its essential character
or remains identifiable.

     1.6.1 For the avoidance of doubt, EVOLUTIONARY IMPROVEMENTS do not include revolutionary
advances, i.e., advances that are different as a matter of kind in

Confidential

Covered by FRE 408 and any state counterpart

2

 

January 6, 2008

comparison to the original product, or that fundamentally change or alter the methodology by
which the original product functions.

1.7 “ILLUMINA FIELD” means any technology that is not based on photolithography. For clarity, what
is carved out of the ILLUMINA FIELD includes (i) arrays made using photolithography, and (ii)
technologies involving instruments, assays, reagents, software, and other products, methods, or
systems, in each and every case capable of being used only with arrays made using photolithography.
By way of example, but not by way of limitation, the technology disclosed in software patent No.
5,795,716 asserted against ILLUMINA in the ACTIONS is within the ILLUMINA FIELD.

II. GRANTS

2.1 AFFYMETRIX, on its behalf and on behalf of its AFFILIATES, hereby grants and agrees to grant to
ILLUMINA and its AFFILIATES, a fully paid-up, irrevocable, worldwide, covenant not to sue ILLUMINA,
its AFFILIATES, and their customers, under and for the lives of the BLOCKING PATENTS, to allow
ILLUMINA and its AFFILIATES to make, use and sell (which includes, without limitation, the right to
have made, offer for sale, export, import, lease, install, service, test, repair, upgrade and
otherwise maintain, provide services using) CURRENT PRODUCTS, and to provide services using CURRENT
PRODUCTS. For the avoidance of doubt, the covenant not to sue granted by AFFYMETRIX under this
Section 2.1 is only granted in the ILLUMINA FIELD.

2.2 For all products other than CURRENT PRODUCTS, and for all services commercialized by ILLUMINA
and its AFFILIATES using products other than CURRENT PRODUCTS, AFFYMETRIX, on its behalf and on
behalf of its AFFILIATES, hereby grants and agrees to grant to ILLUMINA and its AFFILIATES an
irrevocable, worldwide, covenant not to sue ILLUMINA, its AFFILIATES, and their customers, but only
for a period of four (4) years from the Effective Date, under the BLOCKING PATENTS and under any
other patents owned by AFFYMETRIX or its AFFILIATES, or regarding which AFFYMETRIX or its
AFFILIATES has the right to grant licenses or sublicenses. The PARTIES hereby acknowledge and
agree that during such four (4)-year period no damages shall accrue as a result of ILLUMINA’s
commercialization of such products and services. The PARTIES further acknowledge and agree that
the covenant not to sue granted by AFFYMETRIX under this Section 2.2 is only granted in the
ILLUMINA FIELD.

2.3 ILLUMINA, on its behalf and on behalf of its AFFILIATES, agrees, at the request of AFFYMETRIX
during the term of the covenant of Section 2.2, to engage in good faith negotiations with
AFFYMETRIX to provide a license on usual and reasonable commercial terms to AFFYMETRIX and its
AFFILIATES with respect to any patent or patent application owned by ILLUMINA or any of its
AFFILIATES or under which ILLUMINA or any of its AFFILIATES has the right to grant licenses or
sublicenses, in

Confidential

Covered by FRE 408 and any state counterpart

3

 

January 6, 2008

any application area but only (i) for arrays made using photolithography and/or (ii) for
technologies involving instruments, assays, reagents, software, and other products, methods, or
systems, in each and every case capable of being used only with arrays made using photolithography.

2.4 All covenants of this Article II shall become effective only upon receipt by AFFYMETRIX of the
payment specified in Section 4.1 hereof and of the required executed sets of the Agreement.

2.5 Nothing in this Agreement shall limit or in any way affect the rights of either PARTY to
engage in any administrative or judicial proceeding to challenge, invalidate, narrow, condition, or
otherwise affect the term or scope of any patent or patent application of the other PARTY or its
AFFILIATES, or otherwise affect the course of prosecution, maintenance, or enforcement of any
patent or patent application of the other PARTY or its AFFILIATES, including but not limited to
such actions as participating, directly or indirectly, in oppositions, interferences,
reexaminations, or similar proceeding anywhere in the World. It is expressly understood and
agreed, however, that the payment obligations specified in Section 4.1 are irrevocable, and such
payments are to be made by ILLUMINA in accordance with the provisions of Section 4.1 and without
regard to the outcome of any proceeding referred to in this Section 2.5 or any other event or
condition whatsoever.

III. RELEASES, DISMISSALS AND WAIVERS

3.1 AFFYMETRIX, for itself, its AFFILIATES, their successors and assigns, hereby irrevocably and
unconditionally (except for the payment obligations set forth in Section 4.1 hereof) releases,
acquits and forever discharges ILLUMINA and its AFFILIATES, together with their past and present
directors, officers, employees, successors and assigns, and customers (the “ILLUMINA Released
Parties”), in each and every case, from any and all claims and causes of action, of whatever kind
or nature, whether in law or in equity and whether known or unknown, that AFFYMETRIX or its
AFFILIATES now has, ever had, or could in the future have (but for this release) against the
ILLUMINA Released Parties, asserted in, arising out of, resulting from, or relating in any way to
the ACTIONS or that are otherwise based on CURRENT PRODUCTS. Notwithstanding the preceding
provisions of this Section 3.1 or any other provision of this Agreement, all actions to enforce
payment of amounts due under Section 4.1 of this Agreement, and to enforce claims against any
future acts of patent infringement not covered by the covenants in Article II, are expressly
preserved.

3.2 ILLUMINA, for itself, its AFFILIATES, their successors and assigns, hereby irrevocably and
unconditionally (except for the covenants specified in Sections 2.1 and 2.2) releases, acquits and
forever discharges AFFYMETRIX and its AFFILIATES, together with their past and present directors,
officers, employees, successors and assigns, and customers (the “AFFYMETRIX Released Parties”), in
each and every case, from any and all claims and causes of action, of whatever kind or nature,
whether in law or in

Confidential

Covered by FRE 408 and any state counterpart

4

 

January 6, 2008

equity and whether known or unknown, that ILLUMINA or its AFFILIATES now has, ever had, or could in
the future have (but for this release) against the AFFYMETRIX Released Parties, asserted in,
arising out of, resulting from, or relating in any way to the ACTIONS. Notwithstanding the
preceding provisions of this Section 3.2 or any other provision of this Agreement, all actions to
enforce claims against any acts of patent infringement are expressly preserved.

3.3 In consideration of the rights and obligations hereunder, the PARTIES have agreed to
discontinue the ACTIONS and to enter appropriate orders of dismissal of such ACTIONS with prejudice
and without costs and disbursements (and to make such other filings to effectuate the same) in a
Stipulation of Dismissal agreed to by the PARTIES, and each PARTY hereby agrees to give the other
PARTY written evidence thereof.

3.4 The PARTIES assume the risk of any mistake of fact in connection with the subject matter of the
Agreement, the ACTIONS, and with respect to any fact that is now unknown to the PARTIES or to their
officers, directors, employees, agents or representatives. Accordingly, as applicable, the
PARTIES expressly waive all rights under Section 1542 of the Civil Code of California which reads
as follows:

A general release does not extend to claims which the
creditor does not know or suspect to exist in his favor at
the time of executing the release, which if known by him
must have materially affected his settlement with the
debtor.

IV. PAYMENTS

4.1 In complete consideration of the irrevocable and unconditional releases, waivers and covenants
granted hereunder, ILLUMINA shall pay to AFFYMETRIX the sum of Ninety Million U.S. Dollars
($90,000,000.00 U.S.D.) payable within five (5) business days of the receipt by the PARTIES of
written evidence that the ACTIONS have been dismissed as required under Section 3.3.

4.2 All payments to AFFYMETRIX hereunder shall be made by wire transfer to                                         ,
Account Number                     .

4.3 The PARTIES agree that each and all payments due by ILLUMINA to AFFYMETRIX under Section 4.1
are non-refundable, non-creditable against any other payments that may now be due or will ever be
due from ILLUMINA to AFFYMETRIX, fixed, determined, and are not contingent on any future event or
condition whatsoever on the part of AFFYMETRIX or any other entity.

V. THIRD PARTY BENEFICIARIES

Confidential

Covered by FRE 408 and any state counterpart

5

 

January 6, 2008

The PARTIES acknowledge and agree that customers of ILLUMINA and of ILLUMINA’s AFFILIATES are third
party beneficiaries to this Agreement, and that the releases, waivers and covenants granted in
Articles II and III of this Agreement inure to the benefit of all of such customers to the extent
provided therein.

VI. CONFIDENTIALITY AND PRESS RELEASES

This Agreement is strictly confidential and the PARTIES agree not to disclose any of its terms to
third parties, except (i) to governmental entities as required by law, regulation or subpoena or as
otherwise required by law, (ii) to employees, officers, directors, shareholders, and agents of the
PARTIES with a need to know and who are under an obligation to maintain information of this nature
confidential, (iii) to shareholders and investors but in this instance the disclosure should be
limited to the amounts paid, the timeframe of the covenants, and the general nature of the
relationship, or (iv) as required to enforce the legal rights of a PARTY before a court or
arbitrating body having applicable jurisdiction. Notwithstanding the immediately preceding
sentence the PARTIES agree to issue a joint press release to be prepared by ILLUMINA and reviewed
and approved by AFFYMETRIX.

VII. NO ADMISSION; NO WARRANTIES

7.1 The PARTIES agree that they desire to enter into this Agreement to avoid uncertainties
associated with litigation and to reduce their litigation expenses. Consistent therewith, the
PARTIES acknowledge and agree that by entering into this Agreement, (a) ILLUMINA does not in any
way admit, and specifically denies, any infringement of any patents owned by AFFYMETRIX or its
AFFILIATES, and (b) the payment obligations specified in Section 4.1 are irrevocable and
unconditional, and such payments are to be made by ILLUMINA in their entirety and (without limiting
the foregoing) irrespective of any past, present or future contentions or findings regarding
infringement or otherwise regarding the AFFYMETRIX patents.

7.2 THE PARTIES, ON THEIR OWN BEHALF AND ON BEHALF OF THEIR RESPECTIVE AFFILIATES, HEREBY DISCLAIMS
ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, ARISING BY LAW OR OTHERWISE, WITH REGARD TO
THE SUBJECT MATTER OF THIS AGREEMENT (EXCEPT AS EXPRESSLY PROVIDED BELOW IN SECTION 10.7). WITHOUT
LIMITING THE GENERALITY OF THE FOREGOING, NO WARRANTIES OR REPRESENTATIONS ARE EXPRESSED OR IMPLIED
REGARDING THE SCOPE, COVERAGE, VALIDITY OR ENFORCEABILITY OF ANY INTELLECTUAL PROPERTY RIGHTS, OR
REGARDING THE NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OR USE OF ANY
PRODUCTS OR SERVICES UNDER THIS AGREEMENT.

Confidential

Covered by FRE 408 and any state counterpart

6

 

January 6, 2008

VIII. ARBITRATION

8.1 In the event of any dispute or difference of opinion or controversy between the PARTIES arising
out of or in connection with this Agreement or with regard to performance of any obligation
hereunder by either PARTY, both PARTIES shall use their reasonable efforts to settle such dispute
or difference of opinion amicably by good-faith negotiation for a period of fifteen business (15)
days, commencing upon the receipt of written demand for negotiation setting forth clearly and
completely the nature and basis of the dispute and the manner and extent of its proposed
resolution. After the expiration of the 15-day negotiation period, either PARTY may commence an
arbitration to resolve the dispute set forth in the demand for negotiation as set forth below.

8.2 Subject to Section 8.1 hereof, all disputes, differences of opinion, or controversies which may
arise between the PARTIES out of or in relation to or in connection with this Agreement or the
breach thereof, shall be finally settled by arbitration in Los Angeles, California by a panel of
three (3) arbitrators (one of whom shall be a registered patent attorney in the field of
biotechnology) selected in accordance with the Rules of the American Arbitration Association, in
the form pertaining at the time the arbitration is initiated. The PARTIES shall use their best
efforts to complete the arbitration proceeding within three (3) months. The arbitration panel is
hereby empowered by the PARTIES to render whatever judgment or relief under this Agreement
(applying California and U.S. Patent laws, as applicable) is deemed appropriate by the panel,
including the power to award specific performance remedies to enforce this Agreement.

8.3 The losing PARTY as determined by the arbitration panel at the time it makes its award shall
pay the costs of any arbitration entered into pursuant to this Article. However, each PARTY shall
bear its own legal costs, including attorneys fees and experts fees, incurred in connection with
such arbitration.

8.4 Judgment upon the award rendered by the arbitrators or arbitrator, as applicable, shall be
binding, final and unappealable, and may be entered by any court having jurisdiction thereof.

IX. CHANGE OF CONTROL, ASSIGNMENT

9.1 The provisions of this Agreement, including the payment by ILLUMINA and receipt by AFFYMETRIX
of all amounts specified in Section 4.1, shall be binding upon and inure to the benefit of the
PARTIES and their permitted (if any) successors and assigns.

9.2 Each PARTY may assign its rights and obligations hereunder only in connection with the
acquisition of all or substantially all of the assets or equity interests (whether by merger,
recapitalization, reorganization or otherwise) of that PARTY, provided that the acquiring entity
agrees in writing to be fully bound by all obligations of that PARTY

Confidential

Covered by FRE 408 and any state counterpart

7

 

January 6, 2008

under this Agreement, with a copy of such writing provided to the other PARTY within ten (10)
business days of the effective date of such assignment.

9.3 In the event of any assignment by ILLUMINA as permitted hereunder, and/or in the event of any
CHANGE OF CONTROL with respect to ILLUMINA, the covenant not to sue granted by AFFYMETRIX under
Article II shall be limited in scope and shall not extend to any then-existing products or
technology of the acquiring/successor entity.

9.4 In the event of any assignment by AFFYMETRIX as permitted hereunder, and/or in the event of any
CHANGE OF CONTROL with respect to AFFYMETRIX, the right granted by ILLUMINA under Section 2.3 shall
be limited in scope and shall not extend to any then-existing products or technology of the
acquiring/successor entity.

ARTICLE X. MISCELLANEOUS PROVISIONS

10.1 Notice. Any notice or request with reference to this Agreement sent to a PARTY shall
be sent by express delivery to that PARTY’s President (with copy to that PARTY’s General Counsel),
shall specifically refer to this Agreement, and shall be deemed to have been sufficiently given for
all purposes on the third business day following the date of mailing. Unless otherwise specified
in writing, the mailing addresses of the PARTIES shall be as described below:

To ILLUMINA:

ILLUMINA, INC.

Attention President

9885 Towne Center Drive

San Diego, CA 92121

Facsimile: (858) 202-4599

To AFFYMETRIX:

AFFYMETRIX, INC.

Attention President

3380 Central Expressway

Santa Clara, CA 95051

Facsimile: (408) 481-0422

10.2 Severability. If any Article, Section, provision or clause of this Agreement shall be
found or held to be invalid or unenforceable by a court or other decision-making body of competent
jurisdiction, in a judgment from which no further appeal can be taken, the remainder of the
Agreement shall remain valid and enforceable and, to the extent required in the pursuit of this
Agreement, the PARTIES shall negotiate in good faith a substitute, valid and enforceable provision
that reflects the PARTIES’ intent entering into the Agreement.

Confidential

Covered by FRE 408 and any state counterpart

8

 

January 6, 2008

10.3 Entire Agreement — Modification and Waiver. The terms and conditions herein
constitute the entire agreement between the PARTIES and supersede all previous agreements and
understandings, whether oral or written, between the PARTIES with respect to the subject matter
hereof, and no prior agreement or understanding varying or extending the same shall be binding upon
either PARTY. No modification or waiver of any term of this Agreement shall be effective unless
made in a writing signed by both PARTIES.

10.4 Governing Law. This Agreement shall be governed and interpreted in accordance with
the laws of the United States and the State of California, without reference to conflicts of law
principles.

10.5 Interpretation. Articles, Sections, titles, and headings are inserted for convenience
of reference only and are not intended to be a part of or to affect the meaning or interpretation
hereof. As used herein, the term “business days” shall mean all days other than Saturdays, Sundays
or state recognized or U.S. federal holidays. Ambiguities, if any, in this Agreement shall not be
construed against any PARTY, irrespective of which PARTY may be deemed to have authored the
ambiguous provision.

10.6 Counterparts. This Agreement may be executed in identical counterparts, each of which
shall constitute an original and all of which shall constitute one and the same agreement.
Delivery of signatures by means of facsimile or electronic mail shall be as effective as original
signatures.

10.7. Power and Authority. Each PARTY and its undersigned representative hereby represents
and warrants that it has full power and authority to enter into this Agreement, and to grant the
covenants, releases, dismissals and waivers set forth hereunder, on behalf of itself, and its
AFFILIATES, their successors and assigns.

IN WITNESS WHEREOF, the PARTIES have caused their duly authorized officers to execute this
Agreement on the dates indicated below.

	 	 	 
	AFFYMETRIX, INC.

	 	ILLUMINA, INC.
	 
	 	 
	By: /s/ Kevin M. King

	 	By: /s/ Jay Flatley
	 
	 	 
	Name: Kevin M. King

	 	Name: Jay Flatley
	 
	 	 
	Title: President

	 	Title: CEO and President
	 
	 	 
	Date: January 9, 2008

	 	Date: January 6, 2008
	 
	 	 
	Witness: /s/ Suzanne Chan

	 	Witness: Chris Cabou

Confidential

Covered by FRE 408 and any state counterpart

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}]]